SillaJen Inc (215600) - Total Liabilities

Latest as of September 2025: ₩6.58 Billion KRW ≈ $4.46 Million USD

Based on the latest financial reports, SillaJen Inc (215600) has total liabilities worth ₩6.58 Billion KRW (≈ $4.46 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does SillaJen Inc generate cash to assess how effectively this company generates cash.

SillaJen Inc - Total Liabilities Trend (2015–2024)

This chart illustrates how SillaJen Inc's total liabilities have evolved over time, based on quarterly financial data. Check 215600 financial resilience to evaluate the company's liquid asset resilience ratio.

SillaJen Inc Competitors by Total Liabilities

The table below lists competitors of SillaJen Inc ranked by their total liabilities.

Company Country Total Liabilities
Vivien Corp
KO:002070
Korea ₩168.43 Billion
Guangzhou Jet Bio-Filtration Co Ltd
SHG:688026
China CN¥502.66 Million
Cabaletta Bio Inc
NASDAQ:CABA
USA $53.03 Million
CapMan Oyj B
HE:CAPMAN
Finland €143.25 Million
Summit Midstream Corporation
NYSE:SMC
USA $1.32 Billion
Haverty Furniture Companies Inc
NYSE:HVT
USA $345.68 Million
Beijing New Universal Science and Technology Co Ltd
SHE:300472
China CN¥1.06 Billion
Eimskipafélag Íslands hf
IC:EIM
Iceland Ikr352.78 Million

Liability Composition Analysis (2015–2024)

This chart breaks down SillaJen Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is SillaJen Inc worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 18.80 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.06 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.05 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how SillaJen Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for SillaJen Inc (2015–2024)

The table below shows the annual total liabilities of SillaJen Inc from 2015 to 2024.

Year Total Liabilities Change
2024-12-31 ₩17.20 Billion
≈ $11.66 Million
-11.35%
2023-12-31 ₩19.40 Billion
≈ $13.15 Million
-20.83%
2022-12-31 ₩24.51 Billion
≈ $16.61 Million
-8.49%
2021-12-31 ₩26.78 Billion
≈ $18.15 Million
+9.11%
2020-12-31 ₩24.54 Billion
≈ $16.63 Million
-12.67%
2018-12-31 ₩28.11 Billion
≈ $19.05 Million
-14.85%
2017-12-31 ₩33.01 Billion
≈ $22.37 Million
-56.66%
2016-12-31 ₩76.16 Billion
≈ $51.61 Million
+15.23%
2015-12-31 ₩66.09 Billion
≈ $44.79 Million
--

About SillaJen Inc

KQ:215600 Korea Biotechnology
Market Cap
$327.16 Million
₩482.76 Billion KRW
Market Cap Rank
#14599 Global
#519 in Korea
Share Price
₩3495.00
Change (1 day)
-2.37%
52-Week Range
₩2690.00 - ₩4975.00
All Time High
₩121250.15
About

SillaJen, Inc. engages in developing technologies and products using genetic engineering in South Korea. The company develops Pexa-Vec, which is in phase 2 clinical trial to treat renal Cell Carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors. It also develops BAL0891, which is in phase 1 clinical trial for the treatment of solid tumors; and SJ-6… Read more